In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses
Marcin Kortylewski(City of Hope), Hua Yu(City Of Hope National Medical Center), Claudia Kowolik, Stephen J. Forman(City Of Hope National Medical Center), Harris S. Soifer(Kura Oncology (United States)), John J. Rossi(City of Hope), Maciej Kujawski(City Of Hope National Medical Center), Andreas Herrmann(DWI – Leibniz Institute for Interactive Materials), Drew M. Pardoll(Bloomberg (United States)), Andrew Raubitschek, Heehyoung Lee(City of Hope), Lin Wang(Heilongjiang University), Yong Liu(First Affiliated Hospital of Zhengzhou University), Chunmei Yang(City of Hope), Anna Scuto(Institute of Molecular Medicine), Jiehui Deng(NYU Langone Health), Piotr Swiderski(City Of Hope National Medical Center), Richard Jove(Institute of Molecular Medicine)
Cited by 378
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
|New England Journal of Medicine|2015|9.4k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k